iBio Announces Research Collaboration With NIH To Investigate Potential Of Co.'s AI-Driven Epitope Steering Platform For Lassa Fever Vaccine Development
Portfolio Pulse from Benzinga Newsdesk
iBio has announced a research collaboration with the National Institutes of Health (NIH) to investigate the potential of the company's AI-driven epitope steering platform for Lassa fever vaccine development.
June 12, 2023 | 8:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
iBio collaborates with NIH to explore the potential of its AI-driven platform for Lassa fever vaccine development, which could lead to increased interest in the company.
The collaboration with NIH is a positive development for iBio, as it showcases the potential of their AI-driven platform in vaccine development. This partnership could lead to increased interest in the company and its technology, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100